Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 991 to 1005 of 2548 results for methods

  1. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

  2. Preterm labour and birth (NG25)

    This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

  3. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  4. Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (TA1110)

    Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  5. Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

  6. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  7. Permacol for treating anal fistulae (MIB105)

    NICE has developed a medtech innovation briefing (MIB) on Permacol for treating anal fistulae .

  8. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  9. RenalSense Clarity RMS for acute kidney injury (MIB256)

    NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .

  10. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)

    Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.

  11. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

  12. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  13. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  14. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

  15. Baricitinib for moderate to severe rheumatoid arthritis (TA466)

    Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.